KalVista Pharmaceuticals, Inc. (KALV) 

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Show less

Over the last 12 months, insiders at KalVista Pharmaceuticals, Inc. have bought $16.11M and sold $6.83M worth of KalVista Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at KalVista Pharmaceuticals, Inc. have bought $6.76M and sold $3.53M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Venrock Healthcare Capital Partners III, L.P. (10 percent owner) — $32.22M.

The last purchase of 29,747 shares for transaction amount of $437,281 was made by Venrock Healthcare Capital Partners III, L.P. (10 percent owner) on 2024‑02‑08.